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Introduction: Identifying reperfusion and predicting post procedure risk is important
following Percutaneous Coronary Interventions (PCI). An Angiographic Perfusion Score
(APS) combining TIMI flow (TFG) and myocardial perfusion (TMPG) grades before and after
PCI can accurately measure both epicardial and myocardial perfusion and predict Major
Adverse Cardiac Events (MACE).
Patients and methods: APS was calculated in 226 (88 ST elevation Myocardial Infarction
(STEMI) and 138 Non STEMI) patients. Maximum score being 12, reperfusion was defined as
failed: 0e3, partial: 4e9, and full APS: 10e12. Thirty day MACE were observed.
Results: APS identified reperfusion significantly more than TMPG alone (STEMI: 50.6% vs
11.8% ( p < 0.001); Non STEMI, early reperfusion: 69.4% vs 52.8% (p < 0.01) and Non STEMI
late reperfusion: 38.2% vs 7.8%; (p  0.001) respectively. A significantly lower incidence of
MACE was observed in the full as compared to the failed APS group (1.8% vs 22.5%)
(p < 0.001). No differences were noted between TMPG 0e2 (9.8%, 9.4%, 7.3%, respectively)
(p ¼ NS).
Conclusion: Compared to MPG alone APS detects more low risk reperfused patients, post PCI.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Introduction infarction) flow is achieved in the infarct-related coronaryReperfusion therapy in acute myocardial infarction (AMI)
aims at early and sustained reperfusion of the myocardium at
risk. Reperfusion therapy is considered to be angiographically
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i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1e62not always achieved in patients with a successful percuta-
neous coronary intervention (PCI). Several mechanisms have
been suggested to be involved such as no reflow and distal
embolization.5e7
TIMImyocardial perfusion grade (TMPG) is an angiographic
measure of myocardial perfusion at capillary level.4 TMPG has
been found to be useful in both pharmacological and catheter
based reperfusion after AMI and is suggested as a useful
indicator of successful myocardial reperfusion.5 Patients with
both normal epicardial flow and myocardial perfusion have
been shown to have a very low mortality rate of 0.73%.8 Thus,
the TMPG adds additional prognostic information to the
conventional epicardial TFG.9 Incorporation of these two
variables envisaging a combined index of epicardial and
myocardial microvascular blood flow has been suggested as
the Angiographic Perfusion Score (APS).10 APS is a simple,
angiographic metric that takes into account indices of
epicardial and myocardial perfusion, both before and after
PCI, to arrive at a single perfusion grade. The APS is the sum of
the TFG (0e3) added to the TMPG (0e3) before and after PCI,
therefore, a total grade of 0e12 is possible. Failed perfusion
was defined as an APS of 0e3, partial perfusion as an APS of
4e9, and full perfusion as an APS of 10e12. Among STEMI
patients with larger infarct sizes, the association of APS with
the incidence of death or MI, has been found to be statistically
significant with none dying on an APS score of 10e12 and
mortality being higher among patients with a poorer APS
score (0e9) (p ¼ 0.03).10
Evidence thus favors that the APS, which combines grades
of epicardial and tissue level perfusion before and after PCI
may be closely associated with infarct size, and may prove
valuable in clinical risk stratification. Limited prospective
data is available on the use of APS for risk stratification,
especially when compared to the conventional TMPG and
more so in the Non ST elevation MI/unstable angina
(NSTEMI/UA) patient group undergoing PCI. The aim of this
study was to compare assessment of reperfusion post PCI in
acute coronary syndrome (ACS) using the standard TMPG
which takes into consideration post procedure myocardial
perfusion alone, as compared to a more comprehensive
assessment with APS that combines TIMI flow and TMPG
before and after PCI, thereby reflecting both epicardial
and myocardial flow, and to see if APS is a better reflector
of reperfusion as well as favorable short term risk versus
TMPG.2. Methods
Consecutive patients presenting with ACS undergoing PCI
were included in the study. All eligible patients were evalu-
ated with detailed history and thorough clinical evaluation.
Biochemical and hematological parameters including hemo-
globin, total and differential leukocyte count, platelet count,
blood sugar, lipid profile, blood urea, serum creatinine,
sodiumpotassiumwere noted alongwith baseline CK-MB and
Troponin T. Baseline ECG and Echocardiography were per-
formed. Procedural coronary angiograms were evaluated by
two consultants independently; TFG, TMPG, and APS were
calculated before as well as after PCI.2.1. Definitions
The following definitions were used
1) TFG for epicardial flow assessment
TFG 0: No perfusion; no antegrade flow beyond the point of
occlusion,
TFG 1: Penetrationwithout perfusion; the contrastmaterial
passed beyond the area of obstruction but “hanged up” and
failed to opacify the entire coronary bed distal to the
obstruction for the duration of the cine run.
TFG 2: Partial perfusion; the contrast material passed
across the obstruction and opacified the coronary bed distal to
the obstruction, the rate of entry of contrast into the vessel
distal to the obstruction and/or its rate of clearance from the
distal bed being perceptibly slower than its entry into and/or
clearance from comparable areas not perfused by the culprit
vessel and,
TFG 3: Complete perfusion with antegrade flow into the
bed distal to the obstruction occurs as promptly as into the
bed proximal to the obstruction and clearance of contrast
material from the involved bed is as rapid as from an unin-
volved bed in the same vessel or the opposite artery.
2) TIMI Myocardial Perfusion Grade (TMPG) for myocardial
perfusion,
TMPG 0: Dye failed to enter the microvasculature; either
minimal or no ground glass appearance (“blush”) or opacifi-
cation of the myocardium in the distribution of the culprit
artery indicating lack of tissue level perfusion.
TMPG 1: Dye slowly entered but failed to exit the micro-
vasculature; ground glass appearance (“blush”) or opacifica-
tion of themyocardium in the distribution of the culprit lesion
that failed to clear from the microvasculature; dye staining
present on the next injection (approximately, 30 seconds
between injections).
TMPG 2: Delayed entry and exit of dye from the micro-
vasculature; ground glass appearance (“blush”) or opacifica-
tion of themyocardium in the distribution of the culprit lesion
strongly persistent at the end of the washout phase (i.e., dye
strongly persistent after 3 cardiac cycles of the washout
phase; either none or minimal diminution in intensity during
washout) and,
TMPG 3: Normal entry and exit of dye from the microvas-
culature; ground glass appearance (“blush”) or opacification of
the myocardium in the distribution of the culprit lesion that
cleared normally; either gone or only mild/noticeable dimi-
nution in intensity during the washout phase), similar to that
in an uninvolved artery to allow blush grading, the length of
the angiographic run was allowed long enough till the venous
phase of the contrast passage was seen. Blush was assessed
distal to the culprit lesion, and viewswere chosen tominimize
superimposition of noninfarcted territories in the assessment
of the TMPG for the culprit artery. Care was taken not to
mistake filling of the venous system, such as the great cardiac
vein, as blush. Blush was assessed during the same phase of
the cardiac cycle, since it tends to be less intense during the
diastole. These angiographic runs were made in identical
Table 1 e APS and TMPG in patients with STEMI (n[ 88).
PAMI (n ¼ 3) Rescue/routine (n ¼ 85) p
Full APS e 43 (50.6%)
TMPG 3 e 10 (11.8%) <0.001
Partial APS 3 28 (32.9%)
TMPG 1 20 (23.5%) NS
TMPG 2 3 24 (28.2%) NS
Failed APS 14 (16.5%)
TMPG 0 31/(36.47%) <0.01
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1e6 3views according to the infarct-related artery thus assuring
assessment in equal conditions.When the left coronary artery
was involved, the final angiogramwas made in the left lateral
view. When the right coronary artery was involved, the final
angiogram was made in the right oblique view. During
contrast injection, backflow of the contrast agent into the
aorta had to be present in order to be certain of adequate
contrast filling of the epicardial coronary artery. All angio-
grams were made with 6F or 7F guiding catheters following
the standard procedure. An intracoronary bolus of 200 mg
nitroglycerin was given immediately after the angioplasty
procedure to allow adequate quantitative coronary artery
analysis.
3) Angiographic Perfusion Score (APS) was then derived by
calculating the sum of the TIMI flow grade (TFG; 0e3) added
to the TIMI myocardial perfusion grade (TMPG; 0e3) before
and after PCI (total possible grade, 0e12). Failed perfusion
was defined as an APS of 0e3, partial perfusion as APS of
4e9, and full perfusion as a full APS of 10e12.
Post PCI, CK- MB levels, serum creatinine and platelet
counts were obtained 24 h after the procedure. Major Adverse
Coronary Events (MACE)were defined as a composite of death,
reinfarction or ischemic-driven target vessel revasculariza-
tion. Reinfarction was defined as elevation of CK- MB enzyme
levels three times above its upper limit of normal associated
with ischemic symptoms. Follow up was done in patients
coming to the hospital on routine basis after 30 days of
procedure or earlier because of symptoms. A routine echo-
cardiographic examination was done in all patients attending
the PCI clinic to determine the left ventricular ejection fraction
(LVEF).
2.2. Statistical analysis
All analyses were performed with SPSS version 15 software.
All continuous variable values are reported as the mean plus
or minus standard deviation or the median and interquartile
range. The student t test was used for the analysis of contin-
uous variables. When appropriate, the c2 test or Fisher exact
test were used for the analysis of categorical variables.Table 2 e APS and TMPG in patients with NSTEMI
(n[ 138).
Early PCI (36) p Delayed PCI (n ¼ 102) p
Full APS 25 (69.4%) 39 (38.2%%)
TMPG 3 19 (52.8% <0.001 8 (07.8%) <0.001
Partial APS 7 (19.4%) 32 (38.2%)
TMPG 1 5 (13.9%) 52 (50.9%)
TMPG 2 8 (22.2%) NS 16 (15.7%) NS
Failed APS 4 (11.1%) 31 (30.4%)
TMPG 0 4 (11.1%) NS 26 (25.49%) <0.013. Results
A total of 226 patients, 88 (39%) with STEMI and 138 (61%) with
NSTEMI who underwent PCI were evaluated for reperfusion
using the APS and TMPG and their relation with 30 day MACE.
None of our patients received Abciximab or any other GP IIB/
IIIA inhibitor pre PCI. Two boluses of intracoronary integrilin
was given in those with visible thrombus where thrombo-
suction was done. Adenosine was given in routine doses in
case of slow or no reflow situations.
3.1. STEMI (Table 1)
Of the 88 patients presenting with STEMI, primary PCI was
performed in 3 and rescue/routine PCI was undertaken in the
rest. All patient not getting primary PCI received thrombolysiswith Streptokinase. 1.5 million units infusion over 1 hour.
Thrombectomy with thrombuster device was done in 26
patients.
None of those who had a primary procedure achieved
complete reperfusion by either APS or MPG. Out of the 85
with routine/rescue procedures, complete reperfusion as
assessed by TMPG 3 was seen in 11.8% (10/85) and by full APS
in 50.6% (43/85) ( p  0.001). Partial (TMPG 1e2) and failed
(TMPG 0) reperfusion was demonstrated in 23.5% (20/85),
28.23% (24/85), total 51.76% (44/85) and 36.47% (31/85)
respectively. This contrasted with APS assessed partial and
failed reperfusion in 32.9%(28/85) and 16.5%(14/85), respec-
tively (p  0.01) Hence, significantly more patients were
adjudged to have been successfully reperfused by the APS
methodology than by TMPG scoring: 83.5% (71/85) vs 63.5%
(54/85) (p  0.01).3.2. NSTEMI (Table 2)
In this subgroup, 36 patients underwent early PCI, within
48 hours while intervention was delayed to between 2 and 7
days of hospitalization in the remaining 102. Thrombectomy
was done in 16 patients, 12 being in the early intervention
group.
In the early intervention strategy complete reperfusion was
indicated by TMPG 3 in 19/36 (52.8%) and by Full APS in 25/36
(69.4%) (p  0.001) These numbers was significantly greater
than partial reperfusion and failed reperfusion by both MPG
and APS. Partial reperfusion (TMPG 2) was observed in 22.2%
(8/36), minimal reperfusion (TMPG 1) in 13.9% (5/36) and
failure to reperfuse (TMPG 0) in only 11.1% (4/36) (p  0.01 for
trend). Similarly, Partial APS was seen in 19.4% (7/36) and
failed APS in 11.1% (4/36).
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1e64In the delayed intervention subgroup, by TMPG analysis
more patients failed to reperfuse or had minimal perfu-
sion, compared to those who had complete or partial
perfusion (TMPG 0e25.5% (26/102); TMPG 1e51% (52/102)
versus TMPG 2e15.7% (16/102); TMPG 3e7.8% (8/102)
(p ¼ 0.01)). However, by APS analysis no difference in
perfusion status were found: 30.4% (31/102) failed versus
31.4% 32/102; partial versus 38.2% (39/102) full perfusion
(p ¼ 0.43,NS). This contrasted with the early invasive group
where 69.4% (25/36) and 19.4% (7/36) showed full and
partial APS with failed APS in only 11.1% (4/36) (p < 0.001
for trend). These figures point out that when early invasive
strategy is applied in NSTEMI, more patients show
complete reperfusion as indicated by full APS. Also in the
early invasive strategy, APS identifies more reperfusions vs
TMPG alone.
Comparing APS with TMPG in the entire study group, the
percentage of patients with complete and partial perfusion as
identified by TMPG 2 and 3:38.9% (88/226) was less than that
78.31% (177/226 identified by APS, p  0.01). TMPG scoring
hence appeared to indicate that lesser percentage of patients
are reperfused by PCI in ACS and in effect might identify
a smaller number of patients at low risk of MACE post
procedure. That this might be true has been reflected in the
results of clinical outcomes of MACE.4. Clinical outcomes
Major adverse cardiac events (MACE) were defined as
a composite of death, reinfarction or ischemic-driven target
vessel revascularization. Reinfarction was defined as eleva-
tion of CK- MB enzyme levels three times above its upper limit
of normal associated with ischemic symptoms (Table 3).Table 3 e MACE in the APS group.
Failed APS
(n ¼ 49)
Partial APS
(n ¼ 70)
Full APS
(n ¼ 107)
p
Death (5) 4 (8.16%) 1 (1.42%) <0.001
Re MI (4) 2 (4.08%) 1 (1.42%) 1 (0.93%) 0.035
TVR (8) 5 (10.20%) 2 (2.85%) 1 (0.93%) <0.001
Composite (17) 11 (22.4%) 4 (5.71%) 2 (1.8%) <0.0014.1. Deaths
There were a total of 5 deaths in the present study. Four
patients died during hospital stay, three due to persistentTable 4 e MACE in the TMPG group.
TMPG 0 (n ¼ 61) TMPG 1 (n ¼ 32) TM
Death (5) 2 (3.3%) 1 (3.1%)
Re MI (4) 2 (3.3%)
TVR (8) 2 (3.3%) 2 (6.3%)
Composite (17) 6 (9.8%) 3 (9.4%)heart failure and the one due to probable stent thrombosis.
One died suddenly at home on the 22nd post discharge day,
with possible stent thrombosis. Of these, 4 occurred in the
failed APS group (4/24, 16.7%) compared to none in the full APS
category (p ¼ 0.001). One death occurred in the partial APS
group (1/82, 1.2%) (p ¼ NS) (Table 3). In contrast, deaths were
evenly distributed between grades 0e3 of TMPG, differences
not being statistically different.4.2. Reinfactions
There were a total of 4 clinical reinfarction of which 2 were in
the failed APS group (2/24, 8.3%), 1 in the partial APS group (1/
24, 1.2%) and 1 in the full APS group (1/120, 0.8%) (p ¼ 0.038). In
the TMPG analysis, reinfarction was distributed 2 each in the
TMPG 0:3.3% (2/61) and TMPG 2 (2.2% 2/96).4.3. Clinically driven target vessel revascularization
(TVR)
Was done in 8 cases. Of these 5 (62.5%)were in the failed APS
group. Incidence of TVR was 0.8% (1/120) in the full APS,
2.4%(2/82) in the partial APS group (p < 0.001; full vs failed
APS). In the TMPG distribution, TVR occurred in 3.3% (2/61);
6.3%(2/32); 3.1%(3/96) and 2.7%(1/37), respectively in TMPG
categories 0e3, not being statistically different.4.4. Composite of endpoints
A total of 17 composite endpoints (MACE)were observed in the
study. Of these, 64.7% were seen in failed APS. MACE inci-
dence was 1.7%(2/120) in the full APS and this was signifi-
cantly less than 45.8%(11/24) in the failed APS (p < 0.001) and
4.9%(4/82) in the partial APS groups. Thus, a full APS clearly
indicated a good 30 day post procedure outcome. There were
no differences in the baseline characteristics of thosewho had
full, partial or failed APS (Table 5).
This was in contrast to MACE occurrence going by post
procedure TMPG scoring alone. There was no statistical
difference across TMPG 0,1 and 2, but there was a trend
toward lower events with better TMPG. Significant differ-
ences were noted only between TMPG 2 and TMPG 3
(p ¼ 0.001) (Table 4). The incidence of MACE was 9.8% (6/61);
9.4%(3/32); 7.3%(7/96) and 2.7%(1/37), respectively in the
TMPG 0e3 groups.
When APS was estimated using only post intervention TFG
and TMPG with a total score of 6 and patients divided into
failed (0e3) and full (4e6) APS groups, there was noPG 2 (n ¼ 96) TMPG3 (n ¼ 37) p
2 (20.8%) NS
1 (1.04%) 1 (2.7%) NS
3 (3.1%) 1 (2.7%) NS
7 (7.3%) 1 (2.7%) <0.001 for TMPG 2 and 3
Table 5 e Baseline parameters in the three APS groups.
Failed APS n ¼ 24 (10.6%) Partial APS n ¼ 82 (36.3%) Full APS n ¼ 120 (53.1%) p Value
Age 56.4  11.8 58.2  11.1 55.9  10.5 NS
Sex (% male) 66.7 (16/24) 57.3 (47/82) 66.7 (67/120) NS
Prior ACS 12.5 (3/24) 14.6 (12/82) 13.3 (16/120) NS
Smokers 50 (12/24) 53 (44/82) 49.1 (59/120) NS
Diabetes 20.8 (5/24) 23.3 (22/82) 23 (28/120) NS
Hypertension 37.5 (9/24) 41.6 (34/82) 34.2 (41/120) NS
Prior PCI 4.1 (1/24) 9.8 (8/82) 5.8 (7/120) NS
SBP mmHg 138  21.3 134.2  22.1 136.5  22.3 NS
Pulse rate 72.7  15.1 74.8  16.1 74.7  14.5 NS
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 1e6 5statistically significant difference found between the two,
with respect to their MACE. (8.9% failed vs 6.6% full, p ¼ NS).5. Discussion
Percutaneous coronary interventions (PCI) are the treatments
of choice inpatientspresentingwithACS.Patencyof theculprit
vessel or the infarct-related arterymay not be enough to judge
success which will depend more on the prevention of major
coronary events both in the hospital and post discharge.
Establishment of myocardial perfusion as seen by TMPG is
currently the accepted parameter for predicting outcomes
after PCI. In the study by Wong et al,11 TMPG was correlated
withNSTEMI. TMPG0/1flowbothbefore andafter intervention
was associated with increased risk of death or myocardial
infarction at 6months. Using the TMPG,Henriques et al12 were
able to detect a group of patients with reduced myocardial
reperfusion despite normal flow in the epicardial infarct-
related coronary artery. Patients with TMPG 0 or 1 had
a higher mortality compared with patients with TMPG 2 or 3
(13% versus 3%; RR, 4.7; 95% CI, 2.3e9.5; p < 0.001). Also, the
combined incidence of death, recurrentmyocardial infarction,
or revascularization was higher in the group with TMPG 0 or 1
(33% versus 21%; RR, 1.8; 95% CI, 1.1e2.8; p ¼ 0.009). Impaired
myocardial perfusion on the angiogram has been associated
with greater left ventricular end-diastolic pressure13 and the
presence of overt congestive heart failure on presentation.8
However, TMPG tends to completely ignore the epicardial
flow as earlier determined by TIMI flow grading. There is
a bidirectional nature to any causal relationship between
epicardial flow and myocardial perfusion, it is likely that after
restoration of full epicardial patency, impaired myocardial
perfusion may play a major role in reducing antegrade flow in
the epicardial artery. To optimize outcomes, both epicardial
and microvascular perfusion must be restored to normal.
Gibsonet al9 in a substudy fromTIMI 10B concluded thatTMPG
post PCI adds additional long-term prognostic information to
the conventional epicardial TFG and CTFC. But determining
myocardial perfusion after PCI without taking into consideration
the status of perfusion prior to the procedure may not be totally
predictive of outcomes. With these points in view a single
parameter, the APS has evolved integrating pre and post PCI
angiographic perfusion at epicardial andmicro vascular levels.
APS was first investigated in a patient population presenting
with ACS and undergoing PCI by Gibson et al.10.In their study,lower APS was associated with larger infarct sizes and
mortality rate by 30 days increased with worsening APS.
In our study, we found a statistically significant correlation
between APS and all the three MACE parameters and the
composite of all endpoints. As compared to TMPG grading
done post PCI, APS identified more individuals with risk for
future events. The incidence of MACE was significantly higher
as predicted by failed APS (22.4%) in contrast to that reported
in TMPG 0 (9.8%; 0  0.01) (Tables 3 and 4).
Also, conversely we looked at APS vs TMPG alone for
identifying patients at low risk of events post procedure. Our
study found a trend toward lower MACE rate with improve-
ment in TMPG but this was statistically significant only in the
TMPG 3 cohort. Demonstration of TMPG 3 identified 37/226
(16%) as having significantly lower MACE. This was signifi-
cantly less than the 107/226 (47.34%) identified as having low
risk for MACE by full APS (p ¼ 0.01) and 177/226 (78.3%)
(p ¼ 0.001) when partial APS was also taken into consider-
ation. APS thus predicted low risk for 30 days events better
than post procedure TMPG alone. Moreover, while there was
a clear cut difference in MACE in the failed vs successful
perfusion going by APS scoring, such differences could not be
demonstrated on the basis of TMPG assessment alone. MACE
incidence was lowest in the complete perfusion (TMPG 3)
group and highest in the no perfusion (TMPG 0) group
(p ¼ 0.01). However, risk determination is mostly required in
the intermediate perfusion groups where no differences were
found. As one moved on from TMPG 2 to TMPG 3 the differ-
ences significantly jumped (p ¼ 0.001). In the real world
scenario, differentiation between these two grades of TMPG
may be somewhat blurred, but of vital importance sinceMACE
incidence goes down very significantly from partial to
complete perfusion.
This, we propose, can be overcome by the simple scoring
system of APS which combines TMPG and TFG before and
after PCI and takes care of the minor differences arising out of
operator-related interpretation of the angiographic parame-
ters. This combined score not only clearly identifies low risk
patients post PCI but also identifies a larger number of such
patients versus TMPG measured alone post PCI.
Is combining TPMG and TFG just once after PCI rather than
adding scores both before and after PCI, not sufficient to
predict MACE? An analysis of our results showed that no
significant differences in MACE incidences were evident
between failed and successful PCI going by APS scores deter-
mined only once after PCI. Failed APS (0e3) and full APS (4e6)
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1e66by adding TFG and TMPG after PCI showed a MACE incidence
of 8.9% vs 6.4%, respectively; (p ¼ NS).
Short term and long-term clinical outcomes in ACS depend
upon the completeness of revascularization. We report an APS
which is a combined measure of pre and post TFG plus TMPG
scores, as a predictor of risk following a successful PCI. While
many earlier studies have advocated the identification of
patients with high risk depending on the TMPG status 0e1, our
report highlights that APS is superior to the individual
measurements in identifying patients at lower risk for early
clinical events following intervention.6. Conclusion
To optimize outcomes, both epicardial and microvascular
perfusion must be restored to normal. TMPG which is the
favored method of predicting outcomes has the ambiguity of
using a single parameter taken at one point in time, and is low
on sensitivity to identify patients with good prognosis post
PCI. This can be overcome by the simple scoring system of APS
which combines TMPG with TFG before and after PCI and
takes care of the minor differences arising out of operator
related interpretation of the angiographic parameters. APS is
a better discriminator of 30 day MACE than TMPG alone or
combined TFG with TMPG score taken only after PCI. Also,
while most earlier studies with TMPG emphasized on identi-
fying high risk patients depending TMPG status 0e1, we look
at APS as a better predictor of low risk as compared to TMPG.Conflicts of interest
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